Biotech General Discussion

2024 has seen a slew of mergers and acquisitions. Here's a breakdown of 10 major deals within the pharmaceutical and biotechnology sectors that have already taken place this year (FIG. 1 📸). This list highlights the ongoing trend of consolidation within the industry: 👇

Mirati Therapeutics 

Acquired By: Bristol-Myers Squibb

Acquisition Date: Jan. 23, 2024

Acquisition Price: $4.8B

ImmunoGen 

Acquired By: AbbVie

Acquisition Date: Feb. 12, 2024

Acquisition Price: $10.1B

Aiolos Bio 

Acquired By: GlaxoSmithKline (GSK)

Acquisition Date: Feb. 15, 2024

Acquisition Price: $1B

Icosavax 

Acquired By: AstraZeneca (AZN)

Acquisition Date: Feb. 19, 2024

Acquisition Price: $1.1B

Gracell Biotechnologies 

Acquired By: AstraZeneca (AZN)

Acquisition Date: Feb. 22, 2024

Acquisition Price: $1.2B

RayzeBio 

Acquired By: Bristol-Myers Squibb

Acquisition Date: Feb. 26, 2024

Acquisition Price: $4.1B

Ambrx Biopharma 

Acquired By: Johnson & Johnson

Acquisition Date: Mar. 7, 2024

Acquisition Price: $2B

Harpoon Therapeutics 

Acquired By: Merck

Acquisition Date: Mar. 11, 2024

Acquisition Price: $680M

Karuna Therapeutics 

Acquired By: Bristol-Myers Squibb

Acquisition Date: Mar. 18, 2024

Acquisition Price: $14B

CymaBay Therapeutics 

Acquired By: Gilead Sciences

Acquisition Date: Mar. 22, 2024

Acquisition Price: $4.3B

FIG. 1. Major M&A's Announced YTD in 2024.

This article is not investment or legal advice.

Article history:

First published 04/02/24 RF & EJV

#M&A #Mergers #Acquisitions